European Commission logo
English English
CORDIS - EU research results

ONCOgenic Receptor Network of Excellence and Training 2.0

Project description

The encore to a successful training network is honing in on new targets for cancer therapies

Proteins are ubiquitous but they are not all created equal. G-protein-coupled receptors (GPCRs) are the largest and most diverse proteins in the mammalian genome. They are a class of transmembrane proteins that transduce extracellular stimuli or messengers into intracellular signals through interaction of their intracellular domains with G-proteins. The chemokine receptors CXCR4 and ACKR3 are GPCRs that bind the chemokine CXCL12 and they have been implicated in cancer, inflammatory and autoimmune diseases. They are a major target of numerous drug discovery efforts yet their exact mechanisms and roles remain unclear. The ONCORENET2.0 initiative plans to find out more and target new therapies with the help of 15 early stage researchers and recent pioneering work in the field of GPCRs.


Cancer is a major health burden responsible for 20% of European deaths. There is a critical need to understand its fundamental biological mechanisms. G protein-coupled receptors (GPCRs) are cell surface proteins which play an important role in regulating cellular functions integral to cancer biology and, as highly druggable proteins, oncogenic GPCRs are important therapeutic targets. ONCORNET2.0 builds on the success of ONCORNET (Oncogenic GPCR Network of Excellence and Training), a first-in-kind ETN in GPCR drug discovery that has successfully delivered scientific advance and training to talented early stage researchers (ESRs). ONCORNET2.0 will incorporate recent scientific and technological advances to understand and target two oncogenic GPCRs; the chemokine receptors CXCR4 and ACKR3. These are highly expressed in multiple tumours but their role in cancer progression remains poorly understood. We will develop new strategies for CXCR4/ACKR3 modulation (photochemistry, nanobodies) and investigate their effects on oncogenic responses, to yield key new knowledge and potential leads for drug development and commercialisation. ONCORNET2.0 will bring together the leading GPCR research groups in Europe and 15 ESRs. By leveraging on the success and experience of ONCORNET and recent ground-breaking advances in the field of GPCRs (e.g. cryo-EM, CRISPR-Cas, advanced microscopy), ONCORNET2.0 brings a young, gender-balanced team of PIs to target oncogenic GPCRs. The consortium will offer an extensive multidisciplinary training programme for ESRs ensuring their successful incorporation in today’s fast-moving drug development programmes. This programme integrates both research and transferable skill sets through blended learning. Our aim is that, through training these ESRs with interdisciplinary and intersectoral exposure, we will develop the next generation of scientists with skills that are in high demand by the drug development industries but rarely offered academically.


Net EU contribution
€ 1 062 479,52
1081 HV Amsterdam

See on map

West-Nederland Noord-Holland Groot-Amsterdam
Activity type
Higher or Secondary Education Establishments
Total cost
€ 1 062 479,52

Participants (9)